Destination Therapy HeartMate II Implants Drives Thoratec’s Fast Growth
This article was originally published in The Gray Sheet
Executive Summary
“Looking forward, we anticipate that the DT indication will continue to drive growth across the spectrum of centers, but with an increasingly important contribution from smaller transplant and open heart centers,” CEO Gerhard Burbach said.